Annette F. Favorite, Senior Vice President and Chief Human Resources Officer of West Pharmaceutical Services Inc., filed a Form 4 on September 15, 2026, reporting the exercise of stock options and concurrent sales of common stock on September 11, September 14, and September 15, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Three exercise-and-sell transactions: Favorite exercised stock options and sold shares on three separate dates: September 11, September 14, and September 15, 2026.
  • Total shares exercised: 7,524 shares of common stock were acquired via option exercises (2,500 on September 11, 2,500 on September 14, and 2,524 on September 15) at an exercise price of $89.64 per share.
  • Total shares sold: 7,524 shares were disposed of at prices of $345, $355, and $365 per share on the respective transaction dates.
  • Remaining beneficial ownership: Following all reported transactions, Favorite directly held 21,817.8098 shares of common stock.
  • Options fully exhausted: The stock option grant with an exercise price of $89.64 and an expiration date of February 20, 2028, was reduced to 0 derivative securities following the September 15, 2026 exercise.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Details of Annette Favorite's Option Exercises and Share Dispositions at West Pharmaceutical Services

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Annette F. Favorite, identified in the filing as Senior Vice President and Chief Human Resources Officer of West Pharmaceutical Services Inc. (NYSE:WST), reported a series of transactions involving the exercise of stock options and the immediate sale of the resulting common shares. All transactions were conducted under a Rule 10b5-1 plan, as indicated by the checked box on the filing.

The filing discloses that Favorite exercised stock options with a per-share exercise price of $89.64 across three dates. On September 11, 2026, she exercised 2,500 options (transaction code M) and sold 2,500 shares at $345 per share (transaction code S). On September 14, 2026, she exercised another 2,500 options and sold 2,500 shares at $355 per share. On September 15, 2026, she exercised 2,524 options and sold 2,524 shares at $365 per share. After each pair of transactions, her direct beneficial ownership of common stock stood at 21,817.8098 shares, as reported in the filing.

The underlying option grant, according to the filing's explanation of responses, "was granted on February 20, 2018" and "vested in four equal annual installments beginning on February 20, 2019," with an expiration date of February 20, 2028. The derivative securities table confirms that following the September 15, 2026 exercise, the remaining balance of stock options from this grant was reduced to 0. The Form 4 was signed by Louis Lalli as agent for Annette Favorite and dated September 15, 2026.

What Was Disclosed

The filing reported that West Pharmaceutical Services officer Annette F. Favorite exercised 7,524 stock options at $89.64 per share and sold all resulting shares across three dates in September 2026, leaving her with 21,817.8098 directly held common shares.